WallStreetZenWallStreetZen

NASDAQ: ONC
Beone Medicines Ltd Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for ONC

Based on 8 analysts offering 12 month price targets for Beone Medicines Ltd

Min Forecast
$365.00+14.4%
Avg Forecast
$390.88+22.51%
Max Forecast
$408.00+27.88%

Should I buy or sell ONC stock?

Based on 8 analysts offering ratings for Beone Medicines Ltd.

Strong Buy
Strong Buy
6 analysts 75%
Buy
2 analysts 25%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Our proven Zen Rating quant model agrees with analyst consensus with a "Strong Buy" rating. Learn More

Be the first to know when Wall Street analysts revise their ONC stock forecasts and price targets.

ONC stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-11-24Find Out Why
lockedlocked$00.00+00.00%2025-11-18
lockedlocked$00.00+00.00%2025-11-10Find Out Why
lockedlocked$00.00+00.00%2025-11-07
lockedlocked$00.00+00.00%2025-10-20Find Out Why
JP Morgan
Top 4%
97
Strong BuyMaintains$385.00+20.67%2025-10-08Find out why
Barclays
Bottom 5%
5
Strong BuyInitiates Coverage On$385.00+20.67%2025-09-18
Guggenheim
Top 2%
99
Strong BuyMaintains$365.00+14.40%2025-08-07

1 of 1

Forecast return on equity

Is ONC forecast to generate an efficient return?

Company
3,252.07%
Industry
252.48%
Market
227.91%
ONC's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is ONC forecast to generate an efficient return on assets?

Company
1,759.41%
Industry
90.65%
ONC is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ONC earnings per share forecast

What is ONC's earnings per share in the next 3 years based on estimates from 10 analysts?

Avg 1 year Forecast
$1.42+2,742.2%
Avg 2 year Forecast
$3.34+6,572.4%
Avg 3 year Forecast
$5.23+10,353%
ONC's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

ONC revenue forecast

What is ONC's revenue in the next 3 years based on estimates from 11 analysts?

Avg 1 year Forecast
$37.9B+662.71%
Avg 2 year Forecast
$46.3B+830.82%
Avg 3 year Forecast
$53.5B+976.7%
ONC's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

ONC earnings growth forecast

How is ONC forecast to perform vs Biotechnology companies and vs the US market?

Company
371.2%
Industry
43.76%
Market
42.6%
ONC's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
ONC's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
ONC's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

ONC revenue growth forecast

How is ONC forecast to perform vs Biotechnology companies and vs the US market?

Company
120.82%
Industry
101.28%
Market
25.61%
ONC's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
ONC's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

ONC vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ONC$319.06$390.88+22.51%Strong Buy
INSM$197.01$189.40-3.86%Strong Buy
BNTX$94.81$132.00+39.23%Buy
RPRX$38.39$45.75+19.17%Strong Buy
UTHR$493.99$495.08+0.22%Buy
View Top Biotech Stocks

Beone Medicines Stock Forecast FAQ

Is Beone Medicines Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 8 Wall Street analysts covering (NASDAQ: ONC) stock is to Strong Buy ONC stock.

Out of 8 analysts, 6 (75%) are recommending ONC as a Strong Buy, 2 (25%) are recommending ONC as a Buy, 0 (0%) are recommending ONC as a Hold, 0 (0%) are recommending ONC as a Sell, and 0 (0%) are recommending ONC as a Strong Sell.

If you're new to stock investing, here's how to buy Beone Medicines stock.

What is ONC's earnings growth forecast for 2025-2027?

(NASDAQ: ONC) Beone Medicines's forecast annual earnings growth rate of 371.2% is forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 43.76%, and it is also forecast to beat the US market's average forecast earnings growth rate of 42.6%.

Beone Medicines's earnings in 2025 is $68,550,000.On average, 10 Wall Street analysts forecast ONC's earnings for 2025 to be $2,044,328,042, with the lowest ONC earnings forecast at $704,891,099, and the highest ONC earnings forecast at $3,096,485,899. On average, 10 Wall Street analysts forecast ONC's earnings for 2026 to be $4,799,301,396, with the lowest ONC earnings forecast at $3,312,988,165, and the highest ONC earnings forecast at $6,322,585,446.

In 2027, ONC is forecast to generate $7,518,598,629 in earnings, with the lowest earnings forecast at $5,202,096,310 and the highest earnings forecast at $10,165,536,633.

What is ONC's revenue growth forecast for 2025-2027?

(NASDAQ: ONC) Beone Medicines's forecast annual revenue growth rate of 120.82% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 101.28%, and it is also forecast to beat the US market's average forecast revenue growth rate of 25.61%.

Beone Medicines's revenue in 2025 is $4,972,687,000.On average, 11 Wall Street analysts forecast ONC's revenue for 2025 to be $54,560,009,605,801, with the lowest ONC revenue forecast at $52,055,488,374,918, and the highest ONC revenue forecast at $57,939,171,220,588. On average, 11 Wall Street analysts forecast ONC's revenue for 2026 to be $66,586,314,884,481, with the lowest ONC revenue forecast at $62,624,539,198,179, and the highest ONC revenue forecast at $71,734,897,012,758.

In 2027, ONC is forecast to generate $77,021,580,254,283 in revenue, with the lowest revenue forecast at $69,457,667,197,429 and the highest revenue forecast at $86,094,535,684,024.

What is ONC's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: ONC) forecast ROA is 1,759.41%, which is higher than the forecast US Biotechnology industry average of 90.65%.

What is ONC's Price Target?

According to 8 Wall Street analysts that have issued a 1 year ONC price target, the average ONC price target is $390.88, with the highest ONC stock price forecast at $408.00 and the lowest ONC stock price forecast at $365.00.

On average, Wall Street analysts predict that Beone Medicines's share price could reach $390.88 by Nov 24, 2026. The average Beone Medicines stock price prediction forecasts a potential upside of 22.51% from the current ONC share price of $319.06.

What is ONC's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: ONC) Beone Medicines's current Earnings Per Share (EPS) is $0.05. On average, analysts forecast that ONC's EPS will be $1.42 for 2025, with the lowest EPS forecast at $0.49, and the highest EPS forecast at $2.15. On average, analysts forecast that ONC's EPS will be $3.34 for 2026, with the lowest EPS forecast at $2.30, and the highest EPS forecast at $4.40. In 2027, ONC's EPS is forecast to hit $5.23 (min: $3.62, max: $7.07).

What is ONC's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: ONC) forecast ROE is 3,252.07%, which is considered strong.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.